MARS: mutation-adjusted risk score for advanced systemic mastocytosis
1 Vues
• 07/09/23
0
0
Intégrer
administrator
Les abonnés
Andreas Reiter, MD, University Medical Centre, Mannheim, Germany, discusses how a mutation-adjusted risk score (MARS) may improve treatment stratification for advanced systemic mastocytosis (AdvSM). This interview took place at the Myeloproliferative Neoplasms Advances Day 2019 in London, UK.
Montre plus
Commentaires de Facebook
SORT BY-
Meilleures Commentaires
-
Derniers Commentaires